AI in Pharmaceutical Research: AstraZeneca Invests Up to 1.5 Billion Dollars in Biotech Alliance
Reading Time: 2 minutes
Financial Volume: AstraZeneca pays 40 million US dollars upfront to insitro; including milestone payments, the deal amounts to up to 1.46 billion US dollars plus revenue shares. Strategic Focus: The focus is on novel therapies for metabolic-associated steatohepatitis (MASH) and hard-to-treat cardiomyopathies. Efficiency Gains in the Pipeline: The use of machine learning aims to identify biological targets earlier and drastically reduce the effort for lengthy laboratory tests. The British-Swedish pharmaceutical company AstraZeneca...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
